Future Alinia Studies Should Be Multicenter, FDA Recommends
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Future studies of Romark’s antimicrobial Alinia should use a multicenter design, FDA advised in its review of the NDA.